Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Voyager Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window." Voyager further stated that it "no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025." Following this new, Voyager's stock price fell over 20% on February 11, 2025.
In order to be eligible to join the VYGR class action lawsuit, you must have incurred a loss on shares of Voyager Therapeutics, Inc. purchased during the class period listed above.
TOP
